When the U.S. Department of Justice moved to reclassify medical marijuana to a Schedule III drug on April 23, 2026, it set ...
The program, called "Say Something," teaches students how to identify warning signs among their peers and urges them to ...
The move will bring enormous tax benefits to medical marijuana producers and may speed research into its effects, experts say ...
The order places FDA-approved products containing marijuana and state-regulated medical marijuana products at a lower drug ...
A cannabis industry group calls Trump’s reclassification of state-licensed medical marijuana as a less-dangerous drug “the ...
Current federal laws that determine how marijuana and other drugs are classified have “fundamental flaws” that have done “immense damage,” according to a new analysis coauthored by a former Drug ...
Drug shortages remain a thorn in the side of hospital pharmacy leaders nationwide, but one health system has found the right combination of tools to manage them. The American Society of Health-System ...
A House Energy and Commerce subcommittee hearing highlighted the emerging conflict between drug policies and scientific research. Rep. Alexandria Ocasio-Cortez pressed FDA official Dr. Sushmita ...
The review summarizes recent advances, challenges, and future perspectives in targeted drug delivery systems (DDSs) for pancreatic cancer (PC) therapy. Given the dismal prognosis of PC treatment is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results